![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
S Hering, A Savchenko, C Strubing, M Lakitsch and J Striessnig
Institut fur Biochemische Pharmakologie, Universitat Innsbruck, Austria.
To determine which side of L-type Ca2+ channels forms the benzothiazepine binding domain, we tested the effects of a membrane- impermeable, diltiazem-like, Ca2+ antagonist, SQ32,428 [(cis)-1,3,4,5- tetrahydro-4-(4-methoxyphenyl)-3-methyl-6- (trifluoromethyl)-1-[2- trimethylammonio)ethyl]-2H-1-benzazepin-2-o ne], on Ca2+ channels in smooth muscle-like cells (A7r5 cells) and skeletal muscle-like cells (differentiated BC3H1 cells). This permanently charged, quaternary benzazepine bound to the benzothiazepine-selective domain of skeletal muscle Ca2+ channels with a Ki of 1.2 +/- 0.1 microM. Extracellular application of SQ32,428 reversibly blocked whole-cell barium currents through L-type Ca2+ channels in A7r5 and BC3H1 cells with similar potencies (A7r5, IC50 = 86 microM; BC3H1, IC50 = microM). Block was fully reversible, was independent of stimulation frequency, and did not affect steady state inactivation of the channel in A7r5 cells. Intracellular dialysis of the cells with 100 microM SQ32,428 was without effect, but the same concentration of the quaternary phenylalkylamine D890 blocked channel activity from the cytoplasmic side. Our data demonstrate that the benzothiazepine binding domain of L- type Ca2+ channels binds diltiazem-like benzazepine Ca2+ antagonists and is formed by amino acid residues exposed to the extracellular channel surface.
This article has been cited by other articles:
|
|
 |
|
  D. B. Tikhonov and B. S. Zhorov Molecular Modeling of Benzothiazepine Binding in the L-type Calcium Channel J. Biol. Chem., June 20, 2008; 283(25): 17594 - 17604. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. G. Huber, E. Wappl-Kornherr, M. J. Sinnegger-Brauns, J.-C. Hoda, D. Walter-Bastl, and J. Striessnig Opposite Effects of a Single IIIS5 Mutation on Phenylalkylamine and Dihydropyridine Interaction with L-type Ca2+ Channels J. Biol. Chem., December 31, 2004; 279(53): 55211 - 55217. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Dilmac, N. Hilliard, and G. H. Hockerman Molecular Determinants of Ca2+ Potentiation of Diltiazem Block and Ca2+-Dependent Inactivation in the Pore Region of Cav1.2 Mol. Pharmacol., August 1, 2003; 64(2): 491 - 501. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. H. Hockerman, N. Dilmac, T. Scheuer, and W. A. Catterall Molecular Determinants of Diltiazem Block in Domains IIIS6 and IVS6 of L-type Ca2+ Channels Mol. Pharmacol., April 13, 2001; 58(6): 1264 - 1270. [Abstract] [Full Text]
|
|
|
|
|
|
S. Berjukow, F. Gapp, S. Aczel, M. J. Sinnegger, J. Mitterdorfer, H. Glossmann, and S. Hering Sequence Differences between alpha 1C and alpha 1S Ca2+ Channel Subunits Reveal Structural Determinants of a Guarded and Modulated Benzothiazepine Receptor J. Biol. Chem., March 5, 1999; 274(10): 6154 - 6160. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Kraus, S. Hering, M. Grabner, D. Ostler, and J. Striessnig Molecular Mechanism of Diltiazem Interaction with L-type Ca2+ Channels J. Biol. Chem., October 16, 1998; 273(42): 27205 - 27212. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hering, S. Aczel, R. L. Kraus, S. Berjukow, J. Striessnig, and E. N. Timin Molecular mechanism of use-dependent calcium channel block by phenylalkylamines: Role of inactivation PNAS, November 25, 1997; 94(24): 13323 - 13328. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Z. Peterson, B. D. Johnson, G. H. Hockerman, M. Acheson, T. Scheuer, and W. A. Catterall Analysis of the Dihydropyridine Receptor Site of L-type Calcium Channels by Alanine-scanning Mutagenesis J. Biol. Chem., July 25, 1997; 272(30): 18752 - 18758. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hagiwara, S. Adachi-Akahane, and T. Nagao High-Affinity Binding of DTZ323, a Novel Derivative of Diltiazem, to Rabbit Skeletal Muscle L-type Ca++ Channels J. Pharmacol. Exp. Ther., April 1, 1997; 281(1): 173 - 179. [Abstract] [Full Text]
|
|
|
|
|
|
J. Kurokawa, S. Adachi-Akahane, and T. Nagao 1,5-Benzothiazepine Binding Domain Is Located on the Extracellular Side of the Cardiac L-Type Ca2+ Channel Mol. Pharmacol., February 1, 1997; 51(2): 262 - 268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Kraus, B. Reichl, S. D. Kimball, M. Grabner, B. J. Murphy, W. A. Catterall, and J. Striessnig Identification of Benz(othi)azepine-binding Regions within L-type Calcium Channel alpha 1 Subunits J. Biol. Chem., August 16, 1996; 271(33): 20113 - 20118. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
